Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 1, 2027 → Nov 1, 2027
See other at-risk trials from Roswell Park Cancer Institute

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 1, 2026 to Nov 1, 2026 Show 4 more changesShow less
    • Primary completion pushed from Sep 1, 2027 to Nov 1, 2027
    • Study completion pushed from Sep 1, 2028 to Nov 1, 2028
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 2 of 4 entries
  2. Recruitment opened
    • Eligibility criteria expanded, about 7 words
    • Study description expanded, about 1 word
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Secondary endpoints revised (4)
    • Site details revised
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This clinical trial compares two different weight-loss programs, daily continuous calorie energy reduction (CER) versus (vs.) 5:2 intermittent fasting (IF), in preventing progression of kidney (renal) cancer among patients with one or more small renal masses (SRM) undergoing active surveillance (AS). Kidney cancer patients tend to have changes in metabolism that may increase body weight, but weight-loss strategies that work for best for these patients are unknown. The CER program requires a set daily limit for calories. The IF program requires fasting for 2 days a week and normal eating for the remaining 5 days. Both will include self-monitoring with interventionist feedback. This trial may help researchers determine whether the IF program works better than the CER program in improving weight loss, physical health, and/or reducing the risk of kidney cancer progression among patients with small renal masses undergoing AS
Trial Details
NCT Number NCT07714018
Lead Sponsor Roswell Park Cancer Institute
Conditions
(from sponsor)		 Renal Cell Carcinoma (RCC)
Related terms Carcinoma, Renal Cell
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov